Back to search
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
Data up to Jan 2025
Published2014
Citations85
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database